RECALL: Blood Pressure Medication Chlorthalidone

In a voluntary recall, Inventia Healthcare Limited has initiated the recall of specific lots of Chlorthalidone Tablets USP, 25 mg, a commonly prescribed diuretic used to treat high blood pressure (hypertension) and manage fluid retention associated with heart, kidney, or liver disease.

The recall affects approximately 11,460 bottles distributed across the United States by Rising Pharma Holdings Inc.

The recall stems from failed dissolution specifications. Laboratory testing showed that the affected tablets may not break down properly in the body, which could reduce the medication’s effectiveness. This raises the possibility that patients may not receive the full therapeutic benefit for controlling blood pressure or fluid buildup.

The U.S. Food and Drug Administration (FDA) has classified this as a Class II recall, indicating a low probability of serious adverse health consequences, though temporary or reversible effects remain possible. As of the latest reports, no adverse events related to the recall have been documented.

The recall involves two configurations of the 25 mg tablets, both with an expiration date of April 2027:100-count bottles: NDC 64980-599-01, Lot RISA24001
1,000-count bottles: NDC 64980-599-10, Lot RISB24002

Chlorthalidone is a thiazide-like diuretic that helps the kidneys eliminate excess salt and water, lowering blood volume and pressure. It is a long-standing, widely used generic medication, making this recall notable for patients and providers relying on consistent supply and efficacy.

For the most up-to-date official information, visit FDA.gov or consult a healthcare professional.

Share on Facebook

Tweet on Twitter